Perspective Therapeutics (CATX) Projected to Post Earnings on Wednesday

Key Points

• Perspective Therapeutics (CATX) is set to announce its quarterly earnings on Wednesday, August 13th, with anticipated losses of ($0.30) per share and revenue of $0.17 million.
• The stock currently has a consensus rating of "Buy", with an average price target of $12.56 according to multiple analysts' ratings.
• Perspective Therapeutics is developing precision-targeted alpha therapies for oncology, with candidates VMT-a-NET and VMT01 currently in Phase 1/2a clinical trials.

Perspective Therapeutics (NYSE:CATX - Get Free Report) is projected to release its earnings data before the market opens on Wednesday, August 13th. Analysts expect Perspective Therapeutics to post earnings of ($0.30) per share and revenue of $0.17 million for the quarter.

Perspective Therapeutics Stock Down 5.0%

Perspective Therapeutics stock traded down $0.19 during trading on Thursday, reaching $3.63. 646,096 shares of the company's stock were exchanged, compared to its average volume of 956,803. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $16.55. The company's 50-day moving average is $3.66 and its two-hundred day moving average is $2.96.

Analyst Ratings Changes

Several brokerages recently commented on CATX. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a report on Saturday, July 12th. B. Riley reissued a "buy" rating and set a $12.00 target price (up from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Wedbush restated an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Royal Bank Of Canada raised shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and lifted their price target for the stock from $15.00 to $16.00 in a research note on Tuesday, June 3rd. Finally, Truist Financial decreased their price objective on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $12.56.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.